Author
The University of Texas MD Anderson Cancer CenterORCID 0000-0003-0616-2310Unclaimed ORCID profile · follow to get notified of new preprints
6 papers
Recent·Most cited
Neha Arora, Rafael Bravo, Hong Liang…·Yong Zhou
This study shows that lipid acyl chain remodeling via LPCAT3 affects KRAS nanoclustering and oncogenic activity by altering membrane composition.
Neha Arora, Hong Liang, Walaa E. Kattan…·Yong Zhou
This study shows that KRAS G12C and G12D mutants respond differently to lipid acyl chain remodeling, affecting their nanoclustering and signaling activities.
Ryan A. Denu, Anand Kamal Singh, Yingda Jiang…·Kunal Rai
This study shows ATRX loss in sarcomas correlates with poor outcomes and identifies TEAD inhibition as a potential therapy for ATRX-deficient tumors.
Yongkun Wei, Minghui Liu, Er-Yen Yen…·Haoqiang Ying
This study identifies CD24 as an actionable signal activated by KRASG12C inhibition in pancreatic cancer, enhancing macrophage phagocytosis and sensitizing tumors to therapy.
Madelaine Skolastika Theardy, Mitsunobu Takeda, Alexey V. Sorokin…·Wantong Yao
This study identifies the YAP1-SDC1 axis as a driver of resistance to mKRAS inhibitors in gastrointestinal cancers and suggests targeting this axis to overcome resistance.
Ching-Fei Li, Li‐Yuan Bai, Yongkun Wei…·Mien‐Chie Hung
This study shows that ATRA causes ADAR1 degradation and enhances PD-1 blockade to improve antitumor immunity and survival in pancreatic cancer.